<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               17 PATIENT COUNSELING INFORMATION<BR>               <BR>                  <BR>                     Advise pregnant women and females of reproductive potential that PERJETA exposure can result in fetal harm, including embryo-fetal death or birth defects [see Warnings and Precautions (5.1) and Use in Specific Populations (8.1)]<BR>                     <BR>                     Advise females of reproductive potential to use effective contraception while receiving PERJETA and for 6 months following the last dose of PERJETA [see Warnings and Precautions (5.1) and Use in Special Populations (8.6)]<BR>                     <BR>                     Advise nursing mothers treated with PERJETA to discontinue nursing or discontinue PERJETA, taking into account the importance of the drug to the mother [see Use in Specific Populations (8.3)].<BR>                     <BR>                     Encourage women who are exposed to PERJETA during pregnancy to enroll in the MotHER Pregnancy Registry by contacting 1-800-690-6720 [see Warnings and Precautions (5.1) and Use in Specific Populations (8.1)]<BR>                     <BR>                  <BR>                  PERJETA™ (pertuzumab)<BR>                  L01XC13<BR>                  Manufactured by:<BR><BR>                     Genentech, Inc.<BR>A Member of the Roche Group<BR>1 DNA Way<BR>South San Francisco, CA  94080-4990<BR>                  U.S. License No. 1048<BR>                  PERJETA is a trademark of Genentech, Inc.<BR><BR>                     ©2012 Genentech, Inc.<BR>                  Representative sample of labeling (see the HOW SUPPLIED section for complete listing):<BR>               <BR>               <BR>            <BR>         </P></DIV></HTML>